Results 61 to 70 of about 16,949 (211)

Transfersomes as a Carrier for Transdermal Delivery of Acarbose [PDF]

, 2008
This study was to investigate the possible influence of Acarbose on glucagons like peptide-1 release and gastric emptying in type 2 diabetic patients after mixed test meal.
Dinesh Kumar, V
core  

Acarbose Accelerates Wound Healing via Akt/eNOS Signaling indb/dbMice [PDF]

, 2017
Refractory wound is a dreaded complication of diabetes and is highly correlated with EPC dysfunction caused by hyperglycemia. Acarbose is a widely used oral glucose-lowering drug exclusively for T2DM. Previous studies have suggested the beneficial effect
Guofei Ren, Guojun Jiang, Yaping Deng, Xue Han, Jiawen Yu, Yuannan Sun, Jianjun Zhu, Jian Cai   +7 more
core   +1 more source

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale, K. G. Young, P. Cardoso, L. M. Güdemann, T. T. Jansz, A. P. McGovern, A. G. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. M. Shields, J. M. Dennis   +11 more
wiley   +1 more source

Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes

, 2023
Aims: The alpha-glucosidase inhibitor acarbose is an antidiabetic drug delaying assimilation of carbohydrates and, thus, increasing the amount of carbohydrates in the distal parts of the intestines, which in turn increases circulating levels of the gut ...
Hartmann, Bolette, Hansen, Nina L., Nina L. Hansen, Lærke S. Gasbjerg, Bolette Hartmann, Mads M. Helsted, Jens J. Holst, Helsted, Mads M., Filip K. Knop, Hansen, Laura S., Tina Vilsbøll, Laura S. Hansen, Gasbjerg, Lærke S., Kirsa Skov-Jeppesen, Holst, Jens J., Niels B. Dalsgaard, Vilsbøll, Tina, Knop, Filip K., Dalsgaard, Niels B., Skov-Jeppesen, Kirsa   +19 more
core   +1 more source

Antidiabetic Activity of an Ayurvedic Formulation Chaturmukha Rasa: A Mechanism Based Study

Journal of Pharmacopuncture, 2019
Objectives: The objective of this study was to evaluate antidiabetic activity of Chaturmukha rasa based on streptozotocin induced diabetes model, alpha amylase inhibitory activity, alpha Glucosidase inhibitory activity and inhibition of sucrase ...
Akansha Sharma, Raj K Tiwari, Vikas Sharma, Ravindra K Pandey, Shiv Shnakar Shukla   +4 more
doaj   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Acarbose treatment in obesity: a controlled study.

, 1998
Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosaccharidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity.
Ozgen A.G., Yilmaz C., Tüzün M., Hamulu F., Bayraktar F., Kabalak T.   +5 more
core   +1 more source

A Histomorphological Comparative Effects of Metformin, Pioglitazone, Repaglinide and Acarbose on Polycystic Ovary in Mice [PDF]

Journal of Advanced Biomedical Sciences, 2020
Background & Objective: Polycystic ovary syndrome (PCO) is one of the most common causes of infertility due to anovulatory in women. The use of insulin-sensitizing agents was one of the treatments for this syndrome.
fariba noori, paria parto, mehri azadbakht, hamid darvishnia   +3 more
doaj  

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin, Stella Talic, Harvey J. W. Koh, Arul Earnest, Anthony W. Russell, Sophia Zoungas   +5 more
wiley   +1 more source

Drugs for diabetes: part 4 acarbose

, 2011
Acarbose is an alpha-glucosidase inhibitor acting in the gastrointestinal tract producing modest reductions in postprandial hyperglycaemia, with negligible risk of hypoglycaemia and weight gain.
Arungarinathan, Ganesan, Fisher, Miles, McKay, Gerard A.   +2 more
core